Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology shared a post on X:
“Huge kudos to Arcus Biosciences for the commitment to deep translational science while casdatifan is still in an active clinical trial, they are already doing the hard work of building a biomarker framework to understand HIF-2α biology and who benefits most.
This is what dedication to patients looks like. Not waiting until the trial is over to ask the hard questions.
The precision oncology potential here for ccRCC is real.
Watching this program closely.”
Other articles featuring Katy Beckermann on OncoDaily.